Keyphrases
2 Receptor
16%
Acid Type
33%
Acute Pain Management
16%
Aminobutyric Acid
33%
Analgesic
16%
Antidepressants
16%
Atlastin
16%
Cerebrospinal Fluid
16%
Channel Expression
16%
Channel Gating
39%
Childhood Absence Epilepsy
33%
Chronic Pain
16%
Clinical Application
16%
Co-expression
27%
Complementary DNA (cDNA)
16%
Development Application
16%
Drug Development
16%
Electrophysiology
20%
Electrospray Ionization Mass Spectrometry
16%
Expression Level
20%
Febrile Seizures
20%
Flow Cytometry
26%
Fluid Method
16%
GABAA Receptor (GABAAR)
100%
GABAA Receptor Subunits
25%
GABRA6
16%
GABRB3
22%
GABRG2
25%
Genetic Epilepsy
29%
Glycosylation
23%
Glycosylation Site
20%
HEK293 Cells
24%
Liquid Chromatography-electrospray Ionization-mass Spectrometry (LC-ESI-MS)
16%
Low Volume
16%
Method Development & Validation
16%
MS Method
16%
N-linked Glycans
16%
NIPA1
16%
Non-opioid
16%
Ondansetron
16%
Opioid Drugs
16%
Plasma Fluid
16%
Rare Variants
16%
Receptor 2
20%
Receptor Biogenesis
16%
Receptor Expression
20%
Receptor Function
25%
SPG3A
16%
Subunit Stoichiometry
16%
Surface Expression
23%
Neuroscience
Amino Terminal Sequence
6%
Channel Gating
36%
Childhood Absence Epilepsy
33%
Electrophysiology
20%
Endoplasmic Reticulum
8%
Febrile Seizure
19%
Flow Cytometry
23%
GABAA Receptor
83%
GABAergic Inhibition
6%
GABRA6
16%
GABRB3
16%
GABRG2
19%
Gamma-Aminobutyric Acid
40%
Glycan
16%
Glycosylation
33%
Missense Mutation
6%
Receptor
68%
Receptor Expression
16%
Biochemistry, Genetics and Molecular Biology
Atlastin
16%
Biogenesis
19%
Channel Gating
19%
Childhood Absence Epilepsy
16%
Current Amplitude
8%
Electrophysiology
20%
Flow Cytometry
23%
Fluorescence Resonance Energy Transfer
5%
GABAA Receptor
66%
GABRA6
16%
GABRG2
21%
Gamma-Aminobutyric Acid
23%
Genetics
30%
Isoform
5%
Missense Mutation
13%
NIPA1
16%
Population
16%
Rare Variant
16%
Recombinant
5%
Stoichiometry
16%
Transfection
5%
Whole Cell
8%
Wild Type
25%
